Prostate cancer sufferers will be offered pills at ... Researchers discovered that the drug olaparib, one of a new class called PARP inhibitors, could be used to treat a wider range of cancer ...

The anti-cancer drug olaparib may be effective in treating biochemically recurrent prostate cancer without accompanying ...

New data on Lynparza (olaparib), as well as PARP drugs from ... J&J acquired rights to niraparib in prostate cancer from Tesaro in 2016, ahead of the company’s acquisition by GSK in 2019.

Most prostate cancer survivors surveyed reported feeling ... Enhanced antitumor activity was seen with the addition of the PARP inhibitor olaparib to the radioligand lutetium Lu 177 vipivotide ...

This important discovery is the basis for the COBRA study. Carboplatin or Olaparib for BRcA Deficient Prostate Cancer (COBRA) African Americans are disproportionately affected by prostate cancer, ...

"We have shown that olaparib, a drug already approved for use in breast and ovarian cancer, can extend the lives of men with advanced prostate who have defects in the genes BRCA1, BRCA2 or ATM and ...

1 The FDA has approved PARP inhibitors olaparib, rucaparib, and niraparib to treat patients with ovarian cancer, and they are recommended as maintenance therapy for PSROC by both the American ...

Already a mainstay of prostate cancer therapy, Pfizer and Astellas ... challenging AstraZeneca/MSD’s market-leading PARP drug Lynparza (olaparib) in these patients.

Adding Apalutamide Boosts PSA Control in Prostate Cancer Adding apalutamide to androgen deprivation therapy (ADT) prolongs prostate-specific antigen progression-free survival in patients with ...